Loading...
Market
Will Johnson & Johnson receive FDA approval for another chemotherapy-free cancer treatment by August 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA approval announcements and Johnson & Johnson press releases
Story
FDA Approves J&J's RYBREVANT® and LAZCLUZE™ for EGFR-Mutated Lung Cancer
Aug 20, 2024, 11:18 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's chemotherapy-free combination therapy for treating a specific type of non-small cell lung cancer. The treatment, which includes RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), is designed as a first-line option for patients with EGFR-mutated advanced lung cancer. This marks Johnson & Johnson's first FDA approval for a chemotherapy-free lung cancer treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%